目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET RANKING ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 PRICING ANALYSIS*
5.3.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
5.4 VALUE CHAIN ANALYSIS*
5.5 SUPPLY CHAIN ANALYSIS*
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
5.9 REGULATORY LANDSCAPE*
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND ORGANIZATIONS
5.10 TECHNOLOGY ANALYSIS*
5.10.1 KEY TECHNOLOGIES
5.10.1.1 IMMUNOASSAY
5.10.1.2 MOLECULAR DIAGNOSTICS
5.10.2 COMPLIMENTARY TECHNOLOGIES
5.10.2.1 PCR
5.10.3 ADJACENT TECHNOLOGIES
5.10.3.1 MULTIPLEXED POINT-OF-CARE TESTING (XPOCT)
5.10.3.2 NUCLEIC ACID LATERAL FLOW IMMUNOASSAY (NALFIA)
5.11 TRADE DATA ANALYSIS*
5.11.1 IMPORT SCENARIO
5.11.2 EXPORT SCENARIO
5.12 PATENT ANALYSIS*
5.13 KEY CONFERENCES & EVENTS IN 2024-2025*
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA*
5.14.1 KEY STAKEHOLDERS & BUYING PROCESS
5.14.2 BUYING CRITERIA
*Information provided in these segments might not be very exhaustive. This information will be provided on a best-effort basis and availability of data during the primary and secondary research.

6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (USD MILLION, 2021, 2022, 2023, 2028,2029)
6.1 INTRODUCTION
6.2 REAGENTS & KITS
6.3 INSTRUMENTS
6.4 DATA MANAGEMENT SOFTWARE AND SERVICES

7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY (USD MILLION, 2021, 2022, 2023, 2028, 2029)
7.1 INTRODUCTION
7.2 IMMUNOASSAYS
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
7.2.3 IMMUNOFLOURESCENCE ASSAYS
7.2.4 RAPID TESTS
7.2.5 WESTERN BLOTTING
7.2.6 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES
7.3 CLINICAL CHEMISTRY
7.3.1 BASIC METABOLIC PANELS
7.3.2 LIVER PANELS
7.3.3 RENAL PROFILES
7.3.4 LIPID PROFILES
7.3.5 THYROID FUNCTION PROFILES
7.3.6 ELECTROLYTE PANELS
7.3.7 SPECIALYTY CHEMICAL TESTS
7.4 MOLECULAR DIAGNOSTICS
7.4.1 POLYMERASE CHAIN REACTION
7.4.2 ISOTHERMAL NUCLEIC ACID AMPLICATION TECHNOLOGY
7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
7.4.4 IN SITU HYBRIDIZATION
7.4.5 DNA MICROARRAYS
7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
7.5 HEMATOLOGY
7.6 MICROBIOLOGY
7.7 COAGULATION & HEMOSTATSIS
7.8 URINALYSIS
7.9 CHROMATOGRAPHY & MASS SPECTROMETRY

8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN (USD MILLION, 2021, 2022, 2023, 2028, 2029)
8.1 INTRODUCTION
8.2 BLOOD, SERUM, AND PLASMA
8.3 SALIVA
8.4 URINE
8.5 OTHER SPECIMENS

9 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE (USD MILLION, 2021, 2022, 2023, 2028, 2029)
9.1 INTRODUCTION
9.2 LABORATORY TESTS
9.3 POINT OF CARE TESTS

10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION (USD MILLION, 2021, 2022, 2023, 20210, 2029)
10.1 INTRODUCTION
10.2 INFECTIOUS DISEASES
10.3 ONCOLOGY
10.4 ENDOCRINOLOGY
10.5 CARDIOLOGY
10.6 BLOOD SCREENING
10.7 GENETIC TESTING
10.8 AUTOIMMUNE DISEASES
10.9 ALLERGY DIAGNOSTICS
10.10 DRUG MONITORING AND TESTING
10.11 BONE & MINERAL DISORDERS
10.12 COAGULATION TESTING
10.13 BLOOD GROUP TYPING
10.14 OTHER APPLICATIONS

11 IN VITRO DIAGNOSTICS MARKET, BY END USER (USD MILLION, 2021, 2022, 2023, 2028, 2029)
11.1 INTRODUCTION
11.2 HOSPITAL & CLINICS
11.3 CLINICAL LABORATORIES
11.3.1 LARGE REFERENCE LABORATORIES
11.3.2 SMALL & MEDIUM-SIZED LABORATORIES
11.4 BLOOD BANKS
11.5 HOME CARE SETTINGS
11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.7 ACADEMIC INSTITUTES
11.8 OTHER END USERS

12 IN VITRO DIAGNOSTICS MARKET, BY REGION (USD MILLION, 2021, 2022, 2023, 2028, 2029)
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 RECESSION IMPACT
12.2.2 US
12.2.3 CANADA
12.3 EUROPE
12.3.1 RECESSION IMPACT
12.3.2 GERMANY
12.3.3 UK
12.3.4 ITALY
12.3.5 FRANCE
12.3.6 SPAIN
12.3.7 RUSSIA
12.3.8 SWITZERLAND
12.3.9 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 RECESSION IMPACT
12.4.2 CHINA
12.4.3 JAPAN
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 SOUTH KOREA
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 RECESSION IMPACT
12.5.2 BRAZIL
12.5.3 MEXICO
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 RECESSION IMPACT
12.7 GCC COUNTRIES
12.7.1 RECESSION IMPACT
12.7.2 UAE
12.7.3 KINGDOM OF SAUDIA ARABIA
12.7.4 REST OF GCC COUNTRIES

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 REVENUE SHARE ANALYSIS
13.4 MARKET SHARE ANALYSIS
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING : STARTUPS/SMES, 2023
13.7 BRAND COMPARISON
13.8 COMPETITIVE SCENARIO
13.8.1 PRODUCT LAUNCHES
13.8.2 DEALS
13.8.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 MAJOR PLAYERS
14.1.1 ROCHE DIAGNOSTICS
14.1.2 DANAHER CORPORATION
14.1.3 ABBOTT LABORATORIES
14.1.4 SIEMENS HEALTHINEERS
14.1.5 SYSMEX CORPORATION
14.1.6 THERMO FISHER SCIENTIFIC, INC.
14.1.7 BECTON, DICKINSON AND COMPANY
14.1.8 BIOMERIUX SA
14.1.9 BIO-RAD LABORATORIES, INC.
14.1.10 AGILENT TECHNOLOGIES, INC.
14.1.11 QIAGEN N.V.
14.1.12 QUIDELORTHO CORPORATION
14.1.13 DIASORIN S.P.A
14.1.14 ILLUMINA, INC.
14.1.15 HOLOGIC, INC.
14.1.16 REVVITY
14.1.17 GRIFOLS S.P.A
14.1.18 WERFEN
14.2 OTHER PLAYERS
14.2.1 DEVYSER
14.2.2 CHEMBIO DIAGNOSTICS, INC.
14.2.3 SURMODICS, INC.
14.2.4 MENARINI SILICON BIOSYSTEMS
14.2.5 SPEEDX PTY. LTD
14.2.6 GENSPEED BIOTECH GMBH
14.2.7 ACCELERATE DIAGNOSTICS, INC.
14.2.8 MERCK KGAA
14.2.9 CARIS LIFE SCIENCES, INC.
14.2.10 CELLABS
14.2.11 J. MITRA & CO. PVT. LTD.
14.2.12 EPITOPE DIAGNOSTICS
14.2.13 BOSTER BIOLOGICAL TECHNOLOGY
14.2.14 ENZO BIOCHEM
14.2.15 GENETIC SIGNATURES
14.2.16 SAVYON DIAGNOSTICS
14.2.17 TRIVITRON HEALTHCARE
14.2.18 MDXHEALTH
14.2.19 CREATIVE DIAGOSTICS
14.2.20 INBIOS INTERNATIONAL, INC.
14.2.21 MACCURA BIOTECHNOLOGY, CO., LTD.
14.2.22 VELA DIAGNOSTICS
14.2.23 ARKRAY, INC.

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS